Three things pharmacists should know about Ramadan
July 22nd 2013Many Muslims in America recently began their annual celebration of Ramadan, which for many includes fasting or long stretches without eating or drinking. This year, Ramadan began on July 9th and will end on August 7th. For Muslims with chronic illnesses, this can present significant risks.
NCPA CEO testifies before congressional committee
July 17th 2013B. Douglas Hoey, CEO of the National Community Pharmacists Association, this week testified before a congressional committee considering tightening FDA oversight of compounding pharmacies following last year’s New England Compounding Center’s fungal meningitis tragedy.
CMS reports Pioneer ACO cost savings, improved care
July 16th 2013Medicare costs for more than 669,000 beneficiaries within the Pioneer Accountable Care Organizations last year grew at a slower pace, 0.3%, compared to the 0.8% growth rate in spending for those beneficiaries not part of this new model.
Management of antipsychotic medication polypharmacy
July 15th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches that employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1
Prevention of heart attacks by targeting CVD patients
July 15th 2013Face-to-face interaction between pharmacists and patients will be key to the success or failure of the federal government’s Million Hearts initiative to prevent heart attacks and strokes, Salvatore Giorgianni, PharmD, told participants during the June 3 State of Men’s Heart Webinar.
FDA advisers recommend easing Avandia restrictions
July 15th 2013FDA advisers recommended in early June the easing of restrictions on the diabetes drug rosiglitazone (Avandia, GlaxoSmithKline), following an independent re-examination of GSK’s RECORD study conducted by Duke Clinical Research Institute.
Walgreens agrees to pay $80 million in DEA settlement
July 15th 2013Walgreens, the largest pharmacy chain in the United States, has agreed to pay $80 million in civil penalties for record-keeping and dispensing violations under the Controlled Substances Act, according to statements released June 11 by the company and the Drug Enforcement Agency (DEA).
Long-term data reinforce safety profile of dabigatran etexilate mesylate
July 15th 2013Results from the RELY-ABLE trial, the RE-LY extension study, support the long-term safety profile of dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim Pharmaceuticals) 150 mg twice daily in patients with nonvalvular atrial fibrillation (NVAF), according to a study published in Circulation.
Long-term data reinforce safety profile of dabigatran
July 15th 2013Results from the RELY-ABLE trial, the RE-LY extension study, support the long-term safety profile of dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim Pharmaceuticals) 150 mg twice daily in patients with nonvalvular atrial fibrillation (NVAF), according to a study published in Circulation in mid-June.